Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study

Merck (MRK.N) said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.
The seasonal shot met its primary goal in the mid-to-late stage trial, reducing the incidence of lower respiratory tract infections in healthy infants up to one year of age entering their first RSV season.